Abstract
SBI has been used as component of systemic antitumor therapy in the management of 187 advanced cancer patients with Hodgkin's disease (76), lung cancer (70), breast cancer (32) and others (9). The patients were treated at the 15 MeV linear accelerator; 1.5 Gy/min with no shielding was employed. Single dose 1–1.5 Gy to total dose 4–6 Gy (lung corrected) was given to the trunk midplane during 7–10 days in Hodgkin's disease patients. Patients showed good immediate results: discontinuance of B-symptoms (fever, night sweats), diminution of lymph nodes, decrease and disappearance of lung involvement. A dose of 1. 8 Gy to total dose 19 Gy (N = 11) given every day during 2–3 weeks. There was regression of lung involvement, decrease and disappearance of bone pain, diminution of lymph nodes, regression of hepar involvement. SBI is an effective method of radiotherapy in chemotherapy-resistant cases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
